194 related articles for article (PubMed ID: 32381573)
1. Whole-slide image analysis of the tumor microenvironment identifies low B-cell content as a predictor of adverse outcome in patients with advanced-stage classical Hodgkin lymphoma treated with BEACOPP.
Jachimowicz RD; Pieper L; Reinke S; Gontarewicz A; Plütschow A; Haverkamp H; Frauenfeld L; Fend F; Overkamp M; Jochims F; Thorns C; Leo Hansmann M; Möller P; Rosenwald A; Stein H; Reinhardt HC; Borchmann P; von Tresckow B; Engert A; Klapper W
Haematologica; 2021 Jun; 106(6):1684-1692. PubMed ID: 32381573
[TBL] [Abstract][Full Text] [Related]
2. Whole-slide image analysis identifies a high content of Hodgkin Reed-Sternberg cells and a low content of T lymphocytes in tumor microenvironment as predictors of adverse outcome in patients with classic Hodgkin lymphoma treated with ABVD.
Santisteban-Espejo A; Bernal-Florindo I; Perez-Requena J; Atienza-Cuevas L; Maira-Gonzalez N; Garcia-Rojo M
Front Oncol; 2022; 12():1000762. PubMed ID: 36338756
[TBL] [Abstract][Full Text] [Related]
3. [New therapeutic strategies for Hodgkin lymphoma in cooperation of radiation oncology and medical oncology].
Eich HT; Müller RP; Ansén S; Josting A; Engert A; Hansemann K; Pfistner B; Wolf J; Willich N; Diehl V
Rontgenpraxis; 2003; 55(3):114-24. PubMed ID: 15119314
[TBL] [Abstract][Full Text] [Related]
4. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
[TBL] [Abstract][Full Text] [Related]
5. MicroRNA signatures and treatment response in patients with advanced classical Hodgkin lymphoma.
Sánchez-Espiridión B; Martín-Moreno AM; Montalbán C; Figueroa V; Vega F; Younes A; Medeiros LJ; Alvés FJ; Canales M; Estévez M; Menarguez J; Sabín P; Ruiz-Marcellán MC; Lopez A; Sánchez-Godoy P; Burgos F; Santonja C; López JL; Piris MA; Garcia JF
Br J Haematol; 2013 Aug; 162(3):336-47. PubMed ID: 23725219
[TBL] [Abstract][Full Text] [Related]
6. Spatially Resolved Tumor Microenvironment Predicts Treatment Outcomes in Relapsed/Refractory Hodgkin Lymphoma.
Aoki T; Jiang A; Xu A; Yin Y; Gamboa A; Milne K; Takata K; Miyata-Takata T; Chung S; Rai S; Wu S; Warren M; Strong C; Goodyear T; Morris K; Chong LC; Hav M; Colombo AR; Telenius A; Boyle M; Ben-Neriah S; Power M; Gerrie AS; Weng AP; Karsan A; Roth A; Farinha P; Scott DW; Savage KJ; Nelson BH; Merchant A; Steidl C
J Clin Oncol; 2024 Mar; 42(9):1077-1087. PubMed ID: 38113419
[TBL] [Abstract][Full Text] [Related]
7. Standard therapies versus novel therapies in Hodgkin lymphoma.
Gallamini A; Di Raimondo F; La Nasa G; Romano A; Borra A; Greco M
Immunol Lett; 2013; 155(1-2):56-9. PubMed ID: 24140162
[TBL] [Abstract][Full Text] [Related]
8. The Lymphoma-Associated Macrophage to Hodgkin-Reed-Sternberg Cell Ratio Is a Poor Prognostic Factor in Classic Hodgkin Lymphoma Patients.
Procházka V; Papajík T; Dýšková T; Dihel M; Brychtová S; Prouzová Z; Kriegová E; Lukášová M; Hanáčková V
Clin Lymphoma Myeloma Leuk; 2019 Oct; 19(10):e573-e580. PubMed ID: 31377208
[TBL] [Abstract][Full Text] [Related]
9. The combined role of biomarkers and interim PET scan in prediction of treatment outcome in classical Hodgkin's lymphoma: a retrospective, European, multicentre cohort study.
Agostinelli C; Gallamini A; Stracqualursi L; Agati P; Tripodo C; Fuligni F; Sista MT; Fanti S; Biggi A; Vitolo U; Rigacci L; Merli F; Patti C; Romano A; Levis A; Trentin L; Stelitano C; Borra A; Piccaluga PP; Hamilton-Dutoit S; Kamper P; Zaucha JM; Małkowski B; Kulikowski W; Tajer J; Subocz E; Rybka J; Steidl C; Broccoli A; Argnani L; Gascoyne RD; d'Amore F; Zinzani PL; Pileri SA
Lancet Haematol; 2016 Oct; 3(10):e467-e479. PubMed ID: 27692305
[TBL] [Abstract][Full Text] [Related]
10. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma (HL)?
Diehl V; Behringer K
Cancer Invest; 2006 Nov; 24(7):713-7. PubMed ID: 17118782
[TBL] [Abstract][Full Text] [Related]
11. Impact of Bleomycin and Vincristine Dose Reductions in Patients With Advanced Hodgkin Lymphoma Treated With BEACOPP: An Analysis of the German Hodgkin Study Group HD12 and HD15 Trials.
Haverkamp H; Böll B; Eichenauer DA; Sasse S; Fuchs M; Borchmann P; Diehl V; Engert A; von Tresckow B
J Clin Oncol; 2015 Aug; 33(22):2430-6. PubMed ID: 26101245
[TBL] [Abstract][Full Text] [Related]
12. Will BEACOPP be the standard for high risk Hodgkin lymphoma patients in advanced stages?
Diehl V; Fuchs M;
Transfus Apher Sci; 2007 Aug; 37(1):37-41. PubMed ID: 17714996
[TBL] [Abstract][Full Text] [Related]
13. Intensive treatment strategies in advanced-stage Hodgkin's lymphoma (HD9 and HD12): analysis of long-term survival in two randomised trials.
von Tresckow B; Kreissl S; Goergen H; Bröckelmann PJ; Pabst T; Fridrik M; Rummel M; Jung W; Thiemer J; Sasse S; Bürkle C; Baues C; Diehl V; Engert A; Borchmann P;
Lancet Haematol; 2018 Oct; 5(10):e462-e473. PubMed ID: 30290903
[TBL] [Abstract][Full Text] [Related]
14. Could BEACOPP be the new standard for the treatment of advanced Hodgkin's lymphoma?
Diehl V; Behringer K
Cancer Invest; 2006; 24(4):461-5. PubMed ID: 16777701
[TBL] [Abstract][Full Text] [Related]
15. 9p24.1 alterations and programmed cell death 1 ligand 1 expression in early stage unfavourable classical Hodgkin lymphoma: an analysis from the German Hodgkin Study Group NIVAHL trial.
Gerhard-Hartmann E; Goergen H; Bröckelmann PJ; Mottok A; Steinmüller T; Grund J; Zamò A; Ben-Neriah S; Sasse S; Borchmann S; Fuchs M; Borchmann P; Reinke S; Engert A; Veldman J; Diepstra A; Klapper W; Rosenwald A
Br J Haematol; 2022 Jan; 196(1):116-126. PubMed ID: 34520052
[TBL] [Abstract][Full Text] [Related]
16. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial.
Kreissl S; Goergen H; Buehnen I; Kobe C; Moccia A; Greil R; Eichenauer DA; Zijlstra JM; Markova J; Meissner J; Feuring-Buske M; Soekler M; Beck HJ; Willenbacher W; Ludwig WD; Pabst T; Topp MS; Hitz F; Bentz M; Keller UB; Kühnhardt D; Ostermann H; Hertenstein B; Aulitzky W; Maschmeyer G; Vieler T; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Dietlein M; Engert A; Borchmann P;
Lancet Haematol; 2021 Jun; 8(6):e398-e409. PubMed ID: 34048679
[TBL] [Abstract][Full Text] [Related]
17. Molecular profiling of classical Hodgkin lymphoma tissues uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome.
Chetaille B; Bertucci F; Finetti P; Esterni B; Stamatoullas A; Picquenot JM; Copin MC; Morschhauser F; Casasnovas O; Petrella T; Molina T; Vekhoff A; Feugier P; Bouabdallah R; Birnbaum D; Olive D; Xerri L
Blood; 2009 Mar; 113(12):2765-3775. PubMed ID: 19096012
[TBL] [Abstract][Full Text] [Related]
18. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
Nogová L; Reineke T; Brillant C; Sieniawski M; Rüdiger T; Josting A; Bredenfeld H; Skripnitchenko R; Müller RP; Müller-Hermelink HK; Diehl V; Engert A;
J Clin Oncol; 2008 Jan; 26(3):434-9. PubMed ID: 18086799
[TBL] [Abstract][Full Text] [Related]
19. Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy.
Romano A; Parrinello NL; Vetro C; Chiarenza A; Cerchione C; Ippolito M; Palumbo GA; Di Raimondo F
Ann Hematol; 2018 Jun; 97(6):1009-1018. PubMed ID: 29442162
[TBL] [Abstract][Full Text] [Related]
20. Interim PET-results for prognosis in adults with Hodgkin lymphoma: a systematic review and meta-analysis of prognostic factor studies.
Aldin A; Umlauff L; Estcourt LJ; Collins G; Moons KG; Engert A; Kobe C; von Tresckow B; Haque M; Foroutan F; Kreuzberger N; Trivella M; Skoetz N
Cochrane Database Syst Rev; 2019 Sep; 9(9):CD012643. PubMed ID: 31525824
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]